Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption

Nat Commun. 2021 Oct 8;12(1):5907. doi: 10.1038/s41467-021-26066-5.

Abstract

Parkinson's disease and related synucleinopathies are characterized by the abnormal accumulation of alpha-synuclein aggregates, loss of dopaminergic neurons, and gliosis of the substantia nigra. Although clinical evidence and in vitro studies indicate disruption of the Blood-Brain Barrier in Parkinson's disease, the mechanisms mediating the endothelial dysfunction is not well understood. Here we leveraged the Organs-on-Chips technology to develop a human Brain-Chip representative of the substantia nigra area of the brain containing dopaminergic neurons, astrocytes, microglia, pericytes, and microvascular brain endothelial cells, cultured under fluid flow. Our αSyn fibril-induced model was capable of reproducing several key aspects of Parkinson's disease, including accumulation of phosphorylated αSyn (pSer129-αSyn), mitochondrial impairment, neuroinflammation, and compromised barrier function. This model may enable research into the dynamics of cell-cell interactions in human synucleinopathies and serve as a testing platform for target identification and validation of novel therapeutics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Astrocytes / metabolism
  • Blood-Brain Barrier / metabolism*
  • Brain / diagnostic imaging
  • Brain / metabolism*
  • Brain / pathology
  • Dopaminergic Neurons / metabolism
  • Endothelial Cells / metabolism
  • Gliosis / pathology
  • Humans
  • Microglia / metabolism
  • Mitochondria / metabolism
  • Parkinson Disease / metabolism*
  • Pericytes / metabolism
  • Phosphorylation
  • Substantia Nigra / metabolism
  • Synucleinopathies / metabolism*
  • Transcriptome
  • alpha-Synuclein / metabolism*

Substances

  • alpha-Synuclein